OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced an oral presentation and five posters that will highlight the progress of OncoMeds pipeline of anti-cancer biologics at the Annual Meeting of the American Association of Cancer Research in Washington D.C., April 7 9, 2013.

Oral Presentation, Sunday, April 7, 1:30 1:55 pm ET, Room 207, Washington Convention Center

As part of the New Drugs on the Horizon Special Session, Timothy Hoey, PhD, OncoMeds Senior Vice President of Cancer Biology, will discuss, Development of FZD8-Fc (OMP-54F28), a Wnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency.

Poster #218, Sunday, April 7, 1 5 pm ET, Hall A-C, Poster Section 13

R-Spondin (RSPO) signaling drives the growth of multiple human tumor types will be presented by Austin Gurney, PhD, Senior Vice President of Molecular and Cellular Biology at OncoMed, in the Tumor Biology 2 Poster Session.

Poster #3725, Tuesday, April 9, 1 5 pm ET, Hall A-C, Poster Section 12

Anti-DLL4 (demcizumab) Inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts will be presented by Wan-Ching Yen, PhD, Senior Scientist at OncoMed, in the Tumor Biology 35 Poster Session.

Poster #213, Sunday, April 7, 1- 5 pm ET, Hall A-C, Poster Section 13

Novel NOTCH3 activating mutations identified in tumors sensitive to OMP-59R5, a monoclonal antibody targeting the Notch2 and Notch3 receptors will be presented by Breanna Wallace, PhD, Post-Doctoral Research Fellow at OncoMed, in the Cancer Stem Targeting Therapies Poster Session.

Read more:
OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR

Related Post